3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Immunoproliferative Disorders
2
Immune System Diseases
2
Cytokine Release Syndrome
2
Breast Neoplasms
2
Triple Negative Breast Neoplasms
1
Thymoma
1
Thymic epithelial tumor
1
Stomach Neoplasms
1
Prostatic Neoplasms
1
Neurotoxicity Syndromes
1
Neoplasm, Residual
1
Neoplasm Metastasis
1
Myelodysplastic Syndromes
1
Lymphoproliferative Disorders
1
Lymphoma, Non-Hodgkin
1
Lymphoma, B-Cell
1
Lymphoma
1
Lymphohistiocytosis, Hemophagocytic
1
Lymphatic Diseases
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia
1
Hodgkin Disease
1
Epstein-Barr Virus Infections
1
Colorectal Neoplasms
1
Interventions
Valganciclovir
3
Rituximab
3
Cisplatin
3
Vincristine
2
Radiotherapy, Intensity-Modulated
2
Prednisone
2
Matrix-M
2
Gemcitabine
2
Etoposide
2
Doxorubicin
2
Cyclophosphamide
2
pomalidomide
1
dehydroftorafur
1
brincidofovir
1
Watchful Waiting
1
Valacyclovir
1
Tomography, X-Ray Computed
1
Tenofovir
1
Tegafur
1
Taxes
1
Platinum
1
Phantoms, Imaging
1
Paclitaxel
1
Nivolumab
1
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
1
Mitomycin
1
Magnetic Resonance Spectroscopy
1
Lenalidomide
1
Interferons
1
Fluorouracil
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Epstein-Barr Virus Infections
×
AP 1903 reagent
×
1 year
×
Clear all
NCT01494103
2025-07-11
DOTTI
Baylor College of Medicine
Phase 1
Active not recruiting
15 enrolled